Cargando…
Proposed new prognostic model using the systemic immune-inflammation index for primary central nervous system lymphoma: A prospective-retrospective multicohort analysis
PURPOSE: The systemic immune-inflammation index (SII) has been considered a novel prognostic biomarker in several types of lymphoma. Our aims were to determine the best statistical relationship between pretreatment SII and survival and to combination of SII and the Memorial Sloan Kettering Cancer Ce...
Autores principales: | Li, Shengjie, Xia, Zuguang, Cao, Jiazhen, Zhang, Jinsen, Chen, Bobin, Chen, Tong, Zhang, Xin, Zhu, Wei, Li, Danhui, Hua, Wei, Mao, Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681794/ https://www.ncbi.nlm.nih.gov/pubmed/36439151 http://dx.doi.org/10.3389/fimmu.2022.1039862 |
Ejemplares similares
-
Development and Validation of Pretreatment Serum Total Bilirubin as a Biomarker to Predict the Clinical Outcomes in Primary Central Nervous System Lymphoma: A Multicenter Cohort Study
por: Cao, Jiazhen, et al.
Publicado: (2023) -
Evaluation and Application of Population Pharmacokinetic Models for Identifying Delayed Methotrexate Elimination in Patients With Primary Central Nervous System Lymphoma
por: Mao, Junjun, et al.
Publicado: (2022) -
Prognostic impact of peripheral natural killer cells in primary central nervous system lymphoma
por: Lin, Zhiguang, et al.
Publicado: (2023) -
Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
por: Fan, Ni, et al.
Publicado: (2017) -
P1143: ZANUBRUTINIB PLUS CYTARABINE IN PATIENTS WITH REFRACTORY/RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Lin, Zhiguang, et al.
Publicado: (2023)